A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata

Sonali Bhat, Sanjeev Handa, Dipankar De, Sonali Bhat, Sanjeev Handa, Dipankar De

Abstract

Background: Topical corticosteroids are the standard therapy for the treatment of alopecia areata. Recently, topical latanoprost has been found effective in the treatment of eyelash alopecia areata.

Objectives: The objective of this study was to compare the efficacy of topical latanoprost ophthalmic solution (group 1) with that of topical betamethasone diproprionate lotion (group 2) in the treatment of localized alopecia areata.

Methods: This was a single-centre, randomized, two-armed, parallel-group efficacy trial. Fifty consecutive patients with localized alopecia areata were randomized in a 1:1 ratio to receive either topical latanoprost 0.005% ophthalmic solution or topical betamethasone diproprionate 0.05% lotion. Of these 50 patients, 44 patients (21 in group 1 and 23 in group 2) completed the treatment protocol.

Results: The percentage reduction in area involved with alopecia areata at 16 weeks (primary outcome) was lower in latanoprost vs. betamethasone group (median [interquartile range], 11.1 [0-99.1] vs. 100% [13.6-100], P = 0.02). Significantly lesser patients in the latanoprost group had a complete response to treatment as compared to the betamethasone group (6 [24%] vs. 14 [56%], P = 0.02). The median (interquartile range) hair regrowth score was significantly lower in the latanoprost vs. the betamethasone group (1 [0-4.5] vs. 5 [1-5], P = 0.02). Subjects in the betamethasone group showed a more rapid reduction in the involved area.

Limitations: Short duration of treatment and follow-up were limitations of this study.

Conclusion: Our results suggest that topical latanoprost 0.005% ophthalmic solution is less effective but safer than topical betamethasone dipropionate 0.05% lotion in the treatment of localized alopecia areata (clinicaltrials.gov: NCT02350023).

Keywords: Betamethasone; a prostaglandin analogue; corticosteroid; latanoprost; localized alopecia areata.

References

    1. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000; 42:549-66
    1. Hordinsky M, Donati A. Alopecia areata: An evidence-based treatment update. Am J Clin Dermatol. 2014; 15:231-46
    1. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008; 16:CD004413
    1. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997; 124:544-7
    1. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997; 115:1206-8
    1. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: A randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006; 20:1243-7
    1. Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichology. 2011; 3:20-4
    1. Coronel-Perez IM, Rodriguez-Rey EM, Camacho-Martinez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010; 24:481-5
    1. Schlote T. Side-effects and risk profile of latanoprost 0.005% (Xalatan). Ophthalmologe. 2002; 99:724-9
    1. Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: One-year randomized trial. Arch Ophthalmol. 2002; 120:915-22
    1. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, van Denburgh AM, Chen K, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002; 120:1286-93
    1. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002; 47: (Suppl 1)S105-15
    1. Easthope SE, Perry CM. Topical bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002; 19:231-48
    1. Demitsu T, Manabe M, Harima N, Sugiyama T, Yoneda K, Yamada N. Hypertrichosis induced by latanoprost. J Am Acad Dermatol. 2001; 44:721-3
    1. Hart J, Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol. 2004; 137:756-7
    1. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 2000; 118:718-9
    1. Herane MI, Urbina F. Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost. J Eur Acad Dermatol Venereol. 2004; 18:644-5
    1. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 2009; 60:705-6
    1. Ross EK, Bolduc C, Lui H, Shapiro J. Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata. J Am Acad Dermatol. 2005; 53:1095-6
    1. Faghihi G, Andalib F, Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol. 2009; 19:586-7
    1. Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: A pilot study. Dermatology. 2015; 230:308-13
    1. Gandolfi S, Simmons ST, Sturm R, Chen K, van Denburgh AM, Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001; 18:110-21
    1. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012; 66:794-800
    1. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003; 49:96-8

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する